The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Fatma Yazici
dc.contributor.authorGorkemli, Huseyin
dc.contributor.authorColakoglu, Mehmet Cengiz
dc.contributor.authorAktan, Murat
dc.contributor.authorGezginc, Kazim
dc.date.accessioned2024-02-23T14:34:37Z
dc.date.available2024-02-23T14:34:37Z
dc.date.issued2015
dc.departmentNEÜen_US
dc.description.abstractWe aimed to evaluate the clinical efficacy of r-LH supplementation to r-FSH in patients with suboptimal response to ovarian stimulation undergoing assisted reproduction with GnRH-a downregulation and stimulation with r-FSH. One-hundred thirty-seven patients were included in the study; among them 52 showed normal ovarian response to stimulation and composed the control group (Group 1), and 85 showed suboptimal response to stimulation and were divided into two groups. For Group 2 (n = 50), 75 IU/L r-LH was added to the treatment, for Group 3 (n = 35) r-FSH dose was increased by 75 IU/L. IVF results were compared between the groups. Implantation rates were 34.8% in control group, and 36.1% and 15% in LH supplementation group and increased-dose r-FSH group, respectively. Implantation rates were statistically significantly higher in Groups 1 and 2 compared to Group 3 (p < 0.02). Pregnancy rate was noticed in 64.7% of Group 1, 57.8% of Group 2 and at 32.4% of Group 3. Pregnancy rate was significantly higher in Group 2 than Group 3 (p < 0.05). r-LH supplementation is an option for improving IVF outcome in patients with suboptimal ovarian response to ovulation induction with r-FSH during GnRH agonist down-regulation. Particularly, r-LH is recommended as it may have a beneficial action on implantation in selected group.en_US
dc.identifier.doi10.3109/09513590.2014.965675
dc.identifier.endpage144en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue2en_US
dc.identifier.pmid25237892en_US
dc.identifier.scopus2-s2.0-84921366476en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage141en_US
dc.identifier.urihttps://doi.org/10.3109/09513590.2014.965675
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15667
dc.identifier.volume31en_US
dc.identifier.wosWOS:000348205900012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGnrh Agonist Long Protocolen_US
dc.subjectR-Lhen_US
dc.subjectSuboptimal Ovarian Responseen_US
dc.titleThe evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu